<DOC>
	<DOCNO>NCT00004285</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate whether hemodialysis provide 2-pool , variable volume urea kinetic model value 1.05 versus 1.45 reduces mortality morbidity patient end stage renal disease . II . Compare efficacy high versus low flux dialyzer membrane .</brief_summary>
	<brief_title>Phase II Randomized Study Standard Vs High Amount Hemodialysis Using Low Vs High Flux Dialyzer Membranes End Stage Renal Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , multicenter study . Patients stratify center , age , diabetes prior dialysis initiation . Patients randomly assign 1 4 group : moderate dose dialysis , low flux membrane ; high dose dialysis , low flux membrane ; moderate dose dialysis , high flux membrane ; high dose dialysis , high flux membrane . Moderate dose target eKt/V 1.05 high dose 1.45 . The dose delivery dialysis measure monthly equilibrate fractional clearance urea ( eKt/V ) calculate double pool kinetics . Patients dialyze 3 time week short possible time ( minimum 2.5 hour ) , adjust adequate fluid removal . General medical care , protein calorie intake , dialyzer reuse aspects dialysis therapy standardize . The protocol document list approve dialyzer ; unsubstituted cellulosic membrane permit . The intervention phase study 5 year . Patients follow survival .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics End stage renal disease require incenter hemodialysis 3 times/week On hemodialysis least 3 month ( 6 month follow renal transplant ) No schedule renal transplant live donor Prior/Concurrent Therapy No concurrent intervention study unless ancillary protocol No concurrent investigational drug Patient Characteristics Hepatic : Albumin least 2.6 g/dL nephelometry No cirrhosis encephalopathy abnormal PT Renal : Urea clearance ( interdialytic ) great 1.5 mL/min per 35 liter total urea volume Cardiovascular : No New York Heart Association class IV congestive heart failure despite maximal therapy No unstable angina No new onset angina No recent exacerbation frequency , duration , severity angina Pulmonary : No chronic pulmonary disease require supplemental oxygen Other : Not hospitalize acute long term care facility entry No active malignancy require chemotherapy radiotherapy No AIDS No active systemic infection , e.g. , tuberculosis fungal infection No mental incompetence contraindication protocol therapy Not pregnant Geographically available treatment participate institution No 20 miss treatments/year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>end stage renal disease</keyword>
	<keyword>rare disease</keyword>
	<keyword>renal genitourinary disorder</keyword>
</DOC>